Lucence Health
Lucence Health is a biotechnology company specializing in advanced blood-testing technologies for early cancer detection, including its proprietary LiquidHALLMARK liquid biopsy test.
Services
Lucence Health provides advanced cancer screening services focusing on early detection through innovative blood-testing technologies. Their flagship service, LiquidHALLMARK, is a liquid biopsy test that profiles cancer utilizing circulating DNA and RNA from a single blood draw. The company offers a multi-cancer screening service designed to detect cancer at its early stages, leveraging highly sensitive technologies for accurate and comprehensive results.
Products
LiquidHALLMARK is the primary product offered by Lucence Health. This liquid biopsy test can detect clinically significant mutations in 80 genes, fusions in 10 genes, and various somatic variants. It also provides the option to analyze 36 ctRNA targets from a single blood sample, aiding in comprehensive cancer profiling. Another proprietary technology developed by the company is AmpliMark, which has demonstrated over 99% sensitivity in identifying critical biomarkers for lung, breast, and blood cancers.
Proprietary Technologies
Lucence Health has developed proprietary technologies, including AmpliMark, which is known for its high sensitivity in detecting biomarkers associated with lung, breast, and blood cancers. AmpliMark's performance has shown over 99% sensitivity in identifying clinically relevant biomarkers, enhancing the accuracy and reliability of cancer detection through Lucence Health's LiquidHALLMARK test.
Headquarters and Global Offices
Lucence Health is headquartered at 3520 W Bayshore Road, Palo Alto, CA 94303, USA. The company also operates additional offices in prominent locations such as Singapore, Hong Kong, and Suzhou, China, enabling it to serve a global customer base and support its international outreach in cancer diagnostics.
Industry Participation
Lucence Health actively participates in industry events to showcase its advancements in cancer diagnostics. In 2023, the company presented its liquid biopsy technology at the Annual Meeting of the American Society of Clinical Oncology (ASCO), highlighting its commitment to earlier cancer detection and its contribution to the field of oncology.
